ArticleBMC pharmacology & toxicology2026
Targeting a novel tamoxifen-using pathway to preserve ovarian reserve in rats with experimental chemotherapy-induced ovarian failure.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to the increased incidence of cancer in young women, chemotherapy-induced gonad toxicity, such as that caused by cyclophosphamide (CP), is now the main cause of premature ovarian insufficiency (POI).
aimsThe current work investigates how CP damages the rat ovary and whether tamoxifen (TAM) medication and pretreatment can reduce CP by restoring antioxidant and mitochondrial balance.
methodsForty adult female albino rats were randomly allocated into four groups. The control group and CP-induced POI group were used. TAM pretreatment for four weeks prior to CP injection in the third group. A single dosage of TAM was administered concurrently with CP in the fourth group.
resultsIn the group receiving CP, the following observations were observed: a reduction in the ovarian index; a decline in the numbers of primordial and primary follicles; an increase in atretic follicles; a decrease in mRNA expression of insulin-like growth factor 1 (IGF-1) and its receptor (IGF-1R); a significant reduction in anti-Müllerian hormone (AMH); an increase in serum levels of dynamin-related protein (DRP-1); a decrease in serum levels of interleukin 10 (IL-10), nitric oxide (NO), and mitofusin 1 (MFN-1); a damaged ovarian tissues that evaluated histopathologically; an decrease in the number of primordial and primary follicles; an increase in the number of atretic follicles; zona pellucida’s integrity disruption; an decrease in ovarian weights; and an increase in collagen fiber area percentages; a decrease in heme oxygenase-1 (HO-1) immunoreactivity; and an increase in the expression of immunopositive cells for cluster of differentiation 86 (CD86) compared to controls. In contrast, both treatment and pretreatment with TAM improved these effects. With concern to pretreatment with TAM that showed a superior improvement in increasing the number of primordial and primary follicles, improving cortical follicles, enhancing zona pellucida’s integrity and increasing in HO-1immunoreactivity combined with limited regions of collagen fibers.
conclusionOne possible explanation for the protective effects of TAM on ovarian tissue is that it increases IGF-1 mRNA expression, improves mitochondrial dynamic balance, and activates the IL-10/HO-1 pathway, all of which work together to decrease oxidative stress and increase ovarian tissue survival. Based on our research, it appears that a potentially effective regimen for POI caused by CP is pretreatment with TAM. This could lead to a higher percentage of POI disease remission.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.